FDA Brief

Warning letters Drugs

FDA warning letter to

Mentha & Allied Products Private Ltd.

High riskIssued Apr 16, 2025Posted May 13, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.

What happened

FDA inspected the Rampur, Uttar Pradesh facility from September 16 to 25, 2024, and found CGMP deviations in facilities, equipment cleaning, quality-unit data controls, raw-material testing and supplier qualification, laboratory methods, and process/equipment validation. The company's December 10, 2024 response was inadequate because it lacked supporting documentation or adequate evidence of corrective actions.

What FDA found

  1. Buildings and equipment were not kept clean or in good repair, including soiled washrooms, dirty gowning areas, and equipment labeled clean but found with residual product.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  2. The quality unit failed to ensure data integrity, including torn batch records and a torn chromatogram, uncontrolled labeling forms, backfilled batch records, and corrupted backup data without adequate investigation.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The company did not test each incoming raw material batch for identity and relied on supplier certificates without adequately qualifying suppliers.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  4. The company did not test its API against the current USP monograph for two required tests and shipped lots to the U.S. without that assurance.

    FD&C Act section 501(b)
  5. Analytical methods and stability methods were not adequately verified or validated, including no precision acceptance limit and no forced degradation study.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  6. The manufacturing process and major equipment were not adequately validated or qualified to show reproducible API quality.

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)

What FDA wants

FDA tells the company to correct the deviations promptly and respond in writing within 15 working days with corrective actions and supporting documentation; FDA also recommends a qualified CGMP consultant.

Who should pay attention

  • U.S. drugmakers using Mentha APIs
  • companies relying on supplier certificates of analysis
  • brands sourcing APIs or cosmetics from this site

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk